20.12.2024 15:06:52 CET | Thor Medical ASA | Mandatory notification of trade
primary insiders

Oslo, Norway, 20 December 2024: Scatec Innovation AS, a close associate of board
member of Thor Medical ASA John Andersen, has today acquired 1,584,324 shares in
Thor Medical ASA from its controlled subsidiary, Scatec Invest II AS, also a
close associate of John Andersen, with a price of NOK 2.72 per share, reflecting
the last 3 days' vwap for the share. The transaction is an internal group
transaction to settle balances between the parent company and its subsidiary.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

This information is subject to disclosure requirements pursuant to the EU Market
Abuse Regulation article 5 and the Norwegian Securities Trading Act section
5-12.

Contacts

Gisle Bj√∏rnstad, CFO, Scatec Innovation AS, +47 95142892, 
gisle.bjornstad@scatec.no

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - http://www.thormedical.no - 
https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18370282/5453/Download%20announce
ment%20as%20PDF.pdf

20241220 - MAR Form - Scatec Invest II AS to Scatec Innovation AS.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18370282/5452/20241220%20-%20MAR%
20Form%20-%20Scatec%20Invest%20II%20AS%20to%20Scatec%20Innovation%20AS.pdf